Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group

被引：0
作者：
Thomas J. Ettrich
Andreas W. Berger
Lukas Perkhofer
Severin Daum
Alexander König
Andreas Dickhut
Uwe Wittel
Kai Wille
Michael Geissler
Hana Algül
Eike Gallmeier
Jens Atzpodien
Marko Kornmann
Rainer Muche
Nicole Prasnikar
Andrea Tannapfel
Anke Reinacher-Schick
Waldemar Uhl
Thomas Seufferlein
机构：
[1] University of Ulm,Department of Internal Medicine I
[2] Charité University Medicine Berlin,Department of Gastroenterology, Infectious Diseases and Rheumatology
[3] University Medical Center Goettingen,Department of Gastroenterology and Gastrointestinal Oncology
[4] Fulda Hospital,Department of Oncology/Hematology
[5] University of Freiburg,Department of General and Visceral Surgery
[6] Johannes-Wesling-Klinikum Minden,Department of Hematology and medical oncology
[7] Esslingen Hospital,Department of Internal Medicine, Oncology/Hematology, Gastroenterology
[8] Technical University Munich,Department of Internal Medicine II
[9] University of Marburg,Department of Gastroenterology and Endocrinology
[10] Niels-Stensen-Kliniken,Department of Medical Oncology and Hematology
[11] University of Ulm,Department of General and Visceral Surgery
[12] Institute of Epidemiology and Medical Biometry,Department of Oncologie
[13] University of Ulm,Department of Pathology
[14] Asklepios Klinik Barmbek,Department of Internal Medicine
[15] Ruhr-University Bochum,Department of Surgery
[16] Ruhr-University Bochum,undefined
[17] Ruhr-University Bochum,undefined
来源：
BMC Cancer | / 18卷
关键词：
Pancreatic ductal adenocarcinoma; Pancreatic cancer; Resectable; Neoadjuvant chemotherapy; Perioperative chemotherapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 248 条
[1]  
Jemal A(2010)Cancer statistics, 2010 CA Cancer J Clin 60 277-300
[2]  
Siegel R(2014)Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States Cancer Res 74 2913-2921
[3]  
Xu J(2012)Computational modeling of pancreatic cancer reveals kinetics of metastasis suggesting optimum treatment strategies Cell 148 362-375
[4]  
Ward E(2013)S3-guideline exocrine pancreatic cancer Zeitschrift fur Gastroenterologie 51 1395-1440
[5]  
Rahib L(2007)Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial JAMA 297 267-277
[6]  
Smith BD(2017)Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial Lancet 389 1011-1024
[7]  
Aizenberg R(2006)Perioperative chemotherapy versus surgery alone for Resectable Gastroesophageal Cancer N Engl J Med 355 11-20
[8]  
Rosenzweig AB(2008)Most pancreatic cancer resections are R1 resections Ann Surg Oncol 15 1651-1660
[9]  
Fleshman JM(2008)Influence of resection margins and treatment on survival in patients with pancreatic cancer: meta-analysis of randomized controlled trials Arch Surg 143 75-83
[10]  
Matrisian LM(2006)Redefining the R1 resection in pancreatic cancer Br J Surg 93 1232-1237
12345678910